Legal & General Group
SIOX

Legal & General Group’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Legal & General Group’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-630
Closed -$7K – 3402
2018
Q1 		$7K Sell
630
-314
-33% -$5.04K ﹤0.01% 3240
2017
Q4 		$40K Hold
944
– – ﹤0.01% 2948
2017
Q3 		$52K Buy
944
+75
+9% +$12.7K ﹤0.01% 2903
2017
Q2 		$162K Buy
869
+146
+20% +$25.6K ﹤0.01% 2380
2017
Q1 		$86K Sell
723
-46
-6% -$4.82K ﹤0.01% 2629
2016
Q4 		$76K Buy
+769
New +$81K ﹤0.01% 2712

Other funds holding SIOX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Legal & General Group's SIOX Position: Q2 2018 in Review

Legal & General Group sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q2 2018, closing a stake of 630 shares — an estimated $7K sold.

Legal & General Group first reported a position in SIOX in Q4 2016 and held it in 6 quarters. The position peaked at $162K in Q2 2017. 71 funds tracked by Wall St. Rank hold SIOX as of Q2 2018.

  • Legal & General Group reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
  • Legal & General Group sold 630 Sio Gene Therapies Inc. Common Stock shares in Q2 2018, an estimated $7K.
  • Legal & General Group first reported a position in Sio Gene Therapies Inc. Common Stock in Q4 2016 and held it in 6 quarters.
  • Legal & General Group's Sio Gene Therapies Inc. Common Stock position peaked at $162K in Q2 2017.
  • 71 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q2 2018.

Based on Legal & General Group's 13F filing for Q2 2018, filed 10 Aug 2018.